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Background: Hypoxia and snoring-related mechanical trauma contribute to airway inflamma-
tion in obstructive sleep apnoea (OSA). Increased exhaled nitric oxide (FENO), an airway
inflammation marker, has been reported in OSA patients. We propose the measure of NO in
the oral cavity (oNO) as marker of oropharyngeal inflammation in OSA.
Methods: We compared oNO and FENO of 39 OSA patients with those of 26 mild asthmatics
(ASTHMA), 15 patients with chronic rhinitis or rhinosinusitis (CRS) and 24 healthy subjects.
A special device was used for oNO measurement. Apnoea/hypopnoea index (AHI), oxygen de-
saturation index, mean and nadir SaO2 were calculated from the polysomnography.
Results: oNO was significantly increased in OSA (104.2 95%CI 80.2e135.5 ppb) as compared to
ASTHMA (71.9 95%CI 56.3e91.9 ppb; pZ 0.015), CRS (54.4 95%CI 40.2e73.7 ppb; pZ 0.009)
and healthy subjects (63.6 95%CI 59e73 ppb; p< 0.001). oNO was directly related to AHI
(rZ 0.466, pZ 0.003) and to minutes slept with SaO2 <90% (rZ 0.471, pZ 0.011) and it
was inversely related to nadirSaO2 (rZ0.393, pZ 0.018). FENO was highest in asthmatics
(40.3 95%CI 32.5e50.1 ppb) and only slightly elevated in OSA (23.1 95%CI 19,8e28.3 ppb)
and CRS (22.8 95%CI 16.8e32.5 ppb).
Conclusions: The finding that oral NO is increased in OSA and is related to upper airway
obstructive episodes and to hypoxemia severity, strengthens the clinical and pathogenic role
of oral inflammation in OSA.
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Obstructive sleep apnoea (OSA) is a sleep disorder that
leads to metabolic abnormalities and increased cardiovas-
cular risks.1 Airway and systemic inflammation has been
proposed to have a central role in the pathophysiology of
OSA.2 Several studies reported increased inflammatory and
oxidative stress markers in lower airway of OSA patients.
Increased exhaled nitric oxide (FENO) and inflammatory
metabolites were detected in the exhaled air of OSA
compared to healthy subjects.3e5 All these markers were
positively related to the severity of OSA (apnea / hypo-
pnoea index). Airway inflammation in OSA is supposed to be
the consequence of the release of inflammatory cytokines
due to hypoxia and reperfusion cycles during episodes of
apnoea or to snoring-related mechanical trauma. Inflam-
mation has been described to involve the upper airways
including the nose, the uvula, the soft palate and the
pharyngolaryngeal tract. Local upper airway inflammation
promotes oropharyngeal inspiratory muscle dysfunction and
progressive local neurogenic lesion amplifying upper airway
narrowing and collapsibility.6 Localized inflammation with
plasma cell infiltration and interstitial oedema has been
documented in oropharynx, uvula and soft palate biopsies.7
Nitric oxide (NO) is a molecule involved in oxidative stress
and airway inflammation; reactive metabolites of nitric
oxide may cause tissue damage through oxidation and
nitration.8 The role of nitric oxide in inflammatory airway
diseases is well known and the usefulness of NO measure-
ment both in the exhaled air and in the nasal cavity in
asthma and nasal polyposis is widely recognized.9,10
Increased oral nitric oxide production, evaluated by
measuring salivary nitrites and nitrates, has been found in
inflammatory oral diseases as periodontal disease.11e13 We
previously found that oNO can be non invasively assessed
using a special device which separates completely the oral
cavity from the nose and the lower airway. oNO resulted to
be significantly increased in healthy subjects during plaque
deposition14 and in edentulous patients11 We wondered
whether in OSA , oropharyngeal inflammation triggered by
upper airway vibration, might lead to increased oral NO
production.
The objective of the study was to determine whether
oral nitric oxide production is increased in OSA patients and
is related to disease severity. To this purpose we assessed
oNO and FENO in patients with OSA as compared to patient
with mild asthma and chronic rhinosinusitis (lower and
upper airway inflammatory diseases respectively).
Methods
Patients
Thirty nine consecutive OSA patients diagnosed at the Sleep
Medicine Center by polysomnography in the period June
2007eDecember 2008, were enrolled. Polysomnography
was performed according to American Academy of Sleep
Medicine Standards of Practice Committee of the American
Sleep Disorders Association guidelines,15 and OSA was
diagnosed when the apnoea/hypopnoea index (AHI) was
over 10 episodes per hour. Exclusion criteria were currentsmoking, past or present history of lower and upper airway
disease (asthma, allergic rhinitis, chronic rhinosinusitis),
respiratory infections during the last 8 weeks, systemic
disease, use of corticosteroids in the last 2 months,
dentures wearing, periodontal disease or coexisting oral
disease. OSA patients were compared to 15 non smoking
patients with chronic rhinitis or rhinosinusitis (CRS), and to
26 non smoking patients with mild asthma (ASTHMA).
Asthma and CRS patients were selected among those fol-
lowed-up in our clinic, who were not receiving oral or
inhaled corticosteroids and had no oral or periodontal
disease. Diagnosis and classification of rhinitis / rhinosinu-
sitis and asthma were performed according to ARIA16,17 and
GINA18 guidelines respectively. Twenty four non smoking,
non obese, healthy subjects (HS), with no oral disease, with
a mean age of 41 years (range 18e65, 10 men and
14 women) served as control group for oNO measurement.
The study was conducted in accordance with the
Declaration of Helsinki. The study was approved by the
local ethics committee. All the patients gave their informed
consent for the use of their data in the study.
Study design
All subjects underwent history recording, clinical examina-
tion, lung function tests, andmeasurement of oNO and FENO.
Polysomnography
Overnight attended polysomnography was performed using
an H2O system for ambulatory recording (Grass-Telefactor;
ASTRO-Med;WestWarwick, RI) according to the guidelines of
the American Academy of Sleep Medicine Standards of
Practice Committee of the American Sleep Disorders Asso-
ciation,15 using two EEG channels, two electrooculogram
channels, surface mentalis and bilateral anterioris tibialis
electromyography, electrocardiography, oronasal air flow
(two-channel thermistor), respiratory movements (thoracic
and abdominal belts), snoring and body position, and arterial
oxygen saturation (SaO2). Standardized criteria for staging
sleep were used. EEG tracings were used to assess the total
sleep time. Apnea was defined as complete cessation of air
flow of at least 10 s in duration, and hypopnea as >50%
amplitude reduction of air flow lasting 10 s, associated with
4% oxyhemoglobin desaturation during sleep. From the pol-
ysomnography tracing were calculated the following: AHI,
oxygen desaturation index (ODI; number of oxyhemoglobin
desaturations per hour of sleep), mean and nadir SaO2 and
minutes slept with a SaO2 below 90% (SaO2< 90%)
Lung function tests
Spirometry was performed using the computerized
spirometer BAIRES (Biomedin, Padova, Italy). At least three
maximal and repeatable flow-volume curves with vital
capacity (VC) within 5% were recorded. From the curve with
the greatest VC and maximal inspiratory and expiratory
efforts, were calculated FEV1, FEV1/VC ratio, forced mid
expiratory flow (FEF50) and forced mid-inspiratory flow
(FIF50) and their ratio (FEF50/FIF50). VC, FEV1 and FEF50
were expressed as percent of predicted.19
Figure 1 Illustration of oral NO device. Siringe with NO-free
air (1); two-way valve for delivery and withdrawal of air sample
to and from the oral cavity and to the NO meter (2); wide-bore
teflon tube (3); soft mouthpiece (4); Holed metal tube welded
at a right angle to a shaped plate (5).
318 B. Culla et al.Exhaled nitric oxide measurement
Fractional Exhaled Nitric Oxide (FENO) was measured
according to ATS/ERS recommendations20 with a NO
chemiluminescent analyzer (Sievers NOA 280, Sievers,
Boulder, CO, USA) using a sampling flux of 50 mL/min. FENO
values were calculated upon an end expiration plateau 3 s
long at least. The patient performed three acceptable trials
and the mean value was registered.
Oral nitric oxide measurement
Oral NO production was measured using a special device
which consisted of a holed metal tube, welded at right angle
toa shapedplatewhich served topress the tongueagainst the
soft palate so as to isolate the mouth from upper and lower
airway and from gastric cavity. Before themeasurement, the
subjects were asked to rinse accurately their mouth with tap
water. A soft mouthpiece was fitted on the tube, to mantain
themouth closed off and to fasten the position of the device.
A two-way valve connected the plate to a glass syringe, forTable 1 Demographical and clinical characteristics of OSA pati
OSA (NZ 39)
Age, [range] 66 [38e81]a,b
Sex (M/F) 22/17a,c
BMI 30.7 (28.8e32.7)a,c
FVC 100.7 (92.9e108.5)
FEV1 99.4 (91.1e107.8)
FEV1/VC 76.7 (73.5e79.9)
FEF50/ FIF50 112.7 (91.7e133.6)
d
BMI ,FVC, FEV1, FEV1/VC, FEF50/ FIF50 are reported as means with 95
a p< 0.001 OSA vs ASTHMA.
b p< 0.05 OSA VS CRS.
c p< 0.001 OSA vs CRS.
d p< 0.05 OSA VS ASTHMA.delivery and withdrawal of air samples to and from the oral
cavity, and, through a wide-bore Teflon tube (internal
diameter 2 mm), to the NO meter (Fig. 1) Thirty ml NO-free
air (NO below 5 ppb) were injected with a glass syringe
through the device into the closed empty mouth and main-
tained for 30 s; the air was thenwithdrawn and shifted to the
NO chemiluminescence analyzer (SIEVERS 280 NOA, Boulder,
CO).14 oNO measurement was repeated until three values
having a variabilitywithin 5%were obtained. Themeanof the
three values was used in the analysis.
Statistics
Data were analysed with the statistical SPSS software
package (version 13.0 for Windows, Chicago, IL, USA).
Normal distribution of variables were assessed according to
Kolmogorov-Smirnov’s test of normality. In case of non
normal distribution the variables were computed as loga-
rithmic. Comparisons between continuous variables were
estimated with unpaired and paired Student’s t test or
Mann-Whitney test, depending on the distribution of the
variables. Categorical variables were compared with the
Fisher’s exact test. Correlations between parametric or non
parametric variables were obtained using Pearson’s
regression analysis, Spearman’s rank correlation tests, and
logistic regression analysis. For the correlations of oNO with
sleep disturbance, the following sleep parameters were
used: AHI, oxygen desaturation index (ODI; number of
oxyhemoglobin desaturations per hour of sleep), mean and
nadir SaO2, and SaO2< 90%.
A p value< 0.05 was considered to be significant.
Results
Demographical and clinical characteristics of patients are
reported in Table 1. OSA patients, as compared to ASTHMA
and CRS patients, had significantly older age, higher prev-
alence of males and higher BMI. These differences reflect
the characteristics of the diseases, OSA being more
frequent in obese men, adult asthma in women. There were
no difference in lung function parameters apart from
a significantly higher FEF50/ FIF50 ratio in OSA patients
compared to asthmatics (pZ 0.05).ents compared to ASTHMA and CRS groups.
ASTHMA (NZ 26) CRS (nZ 15)
45 [17e68] 50.4 [29e71]
8/18 6/9
24.1 (22.6e25.5) 23.9 (21.9e25.9)
107.7 (99.9e115.5) 113.1(100.5e125.7)
92.6 (85.8e99.4) 99.7 (86.7e112.7)
72.7 (67.9e77.3) 73.4 (67.3e79.5)
77.6 (52.6e102.7) 87 (62.7e111)
% confidence intervals.
Figure 2 Geometric means and SD (bars) of oNO (A) and FENO
(B) in patients with OSA compared to asthmatics (ASTHMA) ,
chronic rhinitis and rhinosinusitis (CRS) and healthy subjects
(HS). # p< 0.001 OSA versus HS; z p< 0.05 OSA versus ASTHMA;
* p< 0.05 OSA vs CRS. y p< 0.05 ASTHMA versus CRS;
U p< 0.001 ASTHMA versus HS;  p< 0.05 CRS versus HS.
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Mean values of oral NO in patients and healthy controls are
reported in Fig. 2, panel A. OSA patients had significantly
increased oNO values (104.2 95%CI 80.2e135.5 ppb) as
compared either with healthy subjects (63.6 95%CI 59.0e
73.0 ppb; p< 0.001) or with both ASTHMA (71.9 95%CI
56.3e91.9 ppb; pZ 0.015) and CRS patients (54.4 95%CIFigure 3 Correlation of oNO with AHI (A) a40.2e73.7 ppb; pZ 0.009). In both ASTHMA and CRS groups
oNO was similar to that of healthy controls.
Mean FENO values in patients and controls are reported in
Fig. 2, panel B. In OSA patients FENO values (23.1 95%CI
19,8e28.3 ppb) were significantly higher than in healthy
subjects (11.0 95%CI 8.7e14.8 ppb; p< 0.001) , and were
similar to those observed in CRS patients (22.8 95%CI 16.8e
32.5 ppb). ASTHMA patients had the highest FENO values
(40.3 95%CI 32.5e50.1 ppb).
No significant relationship between oNO and FENO was
found either in OSA or in CRS, and in ASTHMA.
In OSA patients, oNO production was related to the
severity of sleep disturbances. Actually, oNO was signifi-
cantly positively related to AHI (rZ 0,466, pZ 0.003)
(Fig. 3, A) , to ODI (rZ 0.447, pZ 0.017), to SaO2< 90%
(available in 27 of the 39 patients) (rZ 0.471, pZ 0.011)
(Fig. 3, B) and negatively related to nadir SaO2
(rZ0.393, pZ 0.018). oNO was significantly related to
BMI (rZ 0.505, p< 0.001).
No correlation was found between oNO and spirometric
parameters.
Discussion
The results of the present study show that patients with
OSA have increased production of NO in oral cavity, which is
proportional to the severity of the disease. Since NO is an
inflammatory marker, this finding is in line with prior
studies showing inflammation in the pharynx, uvula, soft
palate and oral cavity of OSA patients.6,7 Oral inflammation
in OSA is supposed to originate in the upper airway, where
repetitive closing and opening during apnoeic episodes
leads to increased production of inflammatory cytokines.21
Pharyngeal collapse is favoured by obesity, that is recog-
nized as a major risk factor for OSAS. This may explain the
correlation we found between BMI and oNO values. Oral
inflammation in OSA may also be a consequence of inter-
mittent hypoxia and reperfusion.22 Low oxygen tension is
a known trigger of activation of polymorphonuclear
neutrophils and macrophages, that interact with the
endothelium causing the release of free oxygen radicals.23nd with SaO2< 90% (B) in OSA patients.
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amplify the oxidative and nitrosative stress by generating
reactive nitrogen oxide species.24 The effect of hypoxia on
NO release is supported by the significant inverse correla-
tion we found between oNO levels and nadir overnight
desaturation.
Interestingly, oral NO in OSA patients was significantly
higher than in patients with other types of upper and lower
inflammatory diseases, such as rhinosinusitis and asthma.
Actually, in both asthma and CRS the major sources of NO
production are far from the mouth, paranasal sinuses in
CRS,24 bronchi and alveoli in asthma.25 These differences in
NO source are reflected by findings of exhaled nitric oxide
measurements. In fact, FENO was highest in asthmatic
patients and mildly increased in both patients with CRS and
those with OSA. The mild increase of FENO levels in OSA
patients is in agreement with several studies reporting
increased inflammatory markers and metabolites in the
exhaled air and condensate of OSA patients.3e5 FENO levels
measured in OSAS may reflect a systemic inflammatory
response.26
In conclusion, the findings of this study indicate that oral
nitric oxide measurement in OSA may be used as a marker of
upper airway obstructive episodes due tomechanical trauma
and of hypoxemia causing local oropharyngeal inflammation.
Follow-up measurements of oNO after effective CPAP
therapywould strengthen thesefindings.Oral NO, through its
ability to amplify oxidative and nitrosative stress, may be
suggested to have a pathogenetic role in OSA.
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